GlaxoSmithKline Pharmaceuticals (500660) Q3 25/26 earnings summary

Executive summary

• Achieved quarterly revenue of INR 1,023 crore, up 8.1% year-over-year, with strong growth in general medicines, specialty, and vaccines portfolios, and expanded specialty portfolio with new oncology assets and regulatory approvals.

• Focused on innovation, digital engagement, and portfolio transformation, reaching 4 million omnichannel touchpoints and driving market share gains.

• Standalone and consolidated unaudited financial results for the quarter and nine months ended 31st December 2025 were approved by the Board on 9th February 2026.

• Leadership team with extensive experience in pharma and regional markets.

Financial highlights

• EBITDA margin reached 35.9%, a 520 basis point improvement year-over-year, with EBITDA up 26.7% to ₹368 crore.

• PAT margin increased to 27.3% (+290bps YoY), with PAT before exceptional items at ₹277 crore.

• EPS for Q3 at ₹16.36, up 9% year-over-year.

• Cash position remains robust at INR 2,426 crore.

• Standalone and consolidated net profit and revenue grew year-over-year, with consolidated revenue at ₹104,126 lakhs and net profit at ₹27,228 lakhs.

Outlook and guidance

• Strategic intent to double business over five years, targeting 12%-13% annual growth to reach INR 8,000 crore revenue.

• Continued focus on scaling oncology, expanding adult immunization, and leveraging digital innovation for customer engagement.

• Base business expected to deliver high single-digit growth, with specialty and vaccine launches providing additional momentum.

• The company continues to monitor regulatory changes, especially regarding new labour codes, and will adjust accounting as needed.